drugset
drugset / Trial / NCT00651911

Fasturtec TLS Treatment / Prophylysis

NCT00651911 ↗

Phase 4 Completed 45 enrolled Sanofi
Non-randomizedSingle-groupOpen-labelTreatment

Summary

An open-label study to determine the efficacy and safety of Rasburicase used for the prevention and treatment of tumor lysis syndrome

Timeline

Start
2003-07
Primary completion
—
Completion
2004-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Rasburicase Protein / enzyme biologic — —

Indications

tumor lysis syndrome